Sunil Healthcare

Who are the top shareholders of the Sunil Healthcare?

The top shareholder of Sunil Healthcare is Anil Kumar Khaitan, who holds 57.95% of the shares. The highest public shareholder is Shailesh Kumar with 5.86%, while individual investors collectively own 17.85%.

The top shareholders of Sunil Healthcare are primarily the promoters, with Anil Kumar Khaitan holding the largest share at 57.95%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Shailesh Kumar, who owns 5.86% of the shares. Additionally, individual investors collectively hold 17.85% of the company's shares.

When is the next results date for Sunil Healthcare?

No Upcoming Board Meetings

Who are in the management team of Sunil Healthcare?

As of March 2021, the management team of Sunil Healthcare includes Anil Kumar Khaitan (Chairman & Managing Director), Sanjay Kumar Kaushik (Non-Executive Director), and several other directors and company secretaries, all contributing to the company's governance and strategic direction.

As of March 2021, the management team of Sunil Healthcare includes the following individuals:<BR><BR>1. Anil Kumar Khaitan - Chairman & Managing Director<BR>2. Sanjay Kumar Kaushik - Non Executive Director<BR>3. Rakesh Mohan - Non-Executive & Independent Director<BR>4. Santosh Kumar Sharma - Company Secretary<BR>5. Harish Pal Kumar - Non-Executive & Independent Director<BR>6. Krishna Venkatachalam Ranjan - Non-Executive & Non-Independent Director<BR>7. Mudita Chaturvedi - Additional Non-Executive Director<BR>8. Bejon Kumar Misra - Non-Executive & Independent Director<BR>9. Satyendu Pattnaik - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Sunil Healthcare do?

Sunil Healthcare Ltd manufactures Empty Hard Gelatin Capsule Shells and HPMC Capsules, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 21 Cr and a market cap of Rs 79 Cr.

Overview: <BR>Sunil Healthcare Ltd is a company engaged in the manufacturing of Empty Hard Gelatin Capsule Shells and HPMC Capsules Shell, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Incorporated in 1973, Sunil Healthcare Ltd was formerly known as Sunil Synchem Ltd. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 21 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 79 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.98 <BR>Return on Equity: -2.12% <BR>Price to Book: 1.19<BR><BR>Contact Details: <BR>Address: 38E/252-A 1st Flr, Vijay Tower Shahpurjat New Delhi New Delhi : 110049 <BR>Phone: 91-11-49435555 <BR>Email: info@sunilhealthcare.com <BR>Website: http://www.sunilhealthcare.com

Has Sunil Healthcare declared dividend?

No Dividend History Available

Who are the peers of the Sunil Healthcare?

Sunil Healthcare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Vivo Bio Tech, Vasundhara Rasy, and Roopa Industries. Sunil Healthcare has below-average management risk and growth, with a 1-year return of -7.26%, better than Rajnish Wellness but lower than its other peers.

Peers: The peers of Sunil Healthcare are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Vivo Bio Tech, Vasundhara Rasy., Roopa Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness, Vivo Bio Tech, and Vasundhara Rasy. Below Average management risk is seen at Sunil Healthcare, Roopa Industries, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Rajnish Wellness, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Sunil Healthcare, Vivo Bio Tech, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Vasundhara Rasy., and Below Average for Sunil Healthcare, Rajnish Wellness, Vivo Bio Tech, Roopa Industries, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Rajnish Wellness at -83.99%. Sunil Healthcare's 1-year return is -7.26%, which is higher than Rajnish Wellness but lower than all other peers. Additionally, the six-month return is negative for Rajnish Wellness, Vasundhara Rasy., and Sunil Healthcare.

What is the technical trend for Sunil Healthcare?

As of June 6, 2025, Sunil Healthcare's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 6 June 2025, the technical trend for Sunil Healthcare has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the bearish stance. Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly, adding to the complexity. The KST is mildly bullish weekly but mildly bearish monthly, and there are no clear trends indicated by Dow Theory. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

How big is Sunil Healthcare?

As of 24th July, Sunil Healthcare Ltd has a market capitalization of 83.00 Cr and reported Net Sales of 83.42 Cr, with a Net Profit loss of 1.42 Cr over the latest four quarters. Shareholder's Funds are 68.22 Cr and Total Assets are valued at 158.50 Cr as of March 2024.

As of 24th July, Sunil Healthcare Ltd has a market capitalization of 83.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 83.42 Cr. However, it experienced a loss of 1.42 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 68.22 Cr and Total Assets valued at 158.50 Cr.

How has been the historical performance of Sunil Healthcare?

Sunil Healthcare's historical performance shows a decline in net sales and profits, with net sales dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, and profit after tax turning negative from 6.68 Cr to -1.42 Cr. However, cash flow from operating activities improved from 7.00 Cr to 11.00 Cr during the same period.

Answer:<BR>The historical performance of Sunil Healthcare shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sunil Healthcare's net sales have decreased from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25. The company's total expenditure also declined from 94.33 Cr in Mar'23 to 73.16 Cr in Mar'25, indicating cost management efforts. Operating profit, which reached 20.66 Cr in Mar'23, fell to 11.60 Cr by Mar'25, while profit before tax transitioned from a positive 9.48 Cr in Mar'23 to a negative 1.22 Cr in Mar'25. Consequently, the profit after tax also turned negative, from 6.68 Cr in Mar'23 to -1.42 Cr in Mar'25. The company's total liabilities increased from 120.79 Cr in Mar'23 to 161.94 Cr in Mar'25, while total assets rose from 120.79 Cr to 161.94 Cr in the same period. Cash flow from operating activities showed improvement, moving from 7.00 Cr in Mar'23 to 11.00 Cr in Mar'25, despite the overall cash flow from financing activities being negative in Mar'25.

Are Sunil Healthcare latest results good or bad?

Sunil Healthcare's latest Q2 FY26 results show a positive turnaround with a net profit of ₹0.91 crores, a 152.78% increase from the previous quarter, and improved revenue and operating margins. However, concerns remain due to low return ratios and high debt levels, resulting in a mixed overall outlook.

Sunil Healthcare's latest results for Q2 FY26 indicate a positive turnaround after a challenging period. The company reported a net profit of ₹0.91 crores, which is a significant increase of 152.78% compared to the previous quarter. This marks a return to profitability after several quarters of losses, showcasing improved operational efficiency.<BR><BR>Revenue for the quarter stood at ₹22.64 crores, reflecting a year-on-year growth of 5.30% and a sequential increase of 6.79%. Additionally, the operating margin improved to 14.49%, the highest in seven quarters, indicating better cost management.<BR><BR>Despite these positive developments, there are concerns regarding the company's overall financial health. The return on capital employed (ROCE) and return on equity (ROE) remain low, at 4.61% and 4.96% respectively, which suggests inefficiencies in capital deployment. Furthermore, the company's high leverage, with a debt-to-EBITDA ratio of 6.87 times, raises questions about its financial sustainability.<BR><BR>In summary, while Sunil Healthcare's latest results show encouraging signs of recovery and improved profitability, structural challenges such as weak return ratios and high debt levels persist, making the overall outlook mixed.

Should I buy, sell or hold Sunil Healthcare?

Is Sunil Healthcare overvalued or undervalued?

As of November 20, 2025, Sunil Healthcare is considered overvalued with a high PE ratio of 42.04 and an EV to EBITDA of 10.06, despite a low PEG ratio of 0.18, indicating inefficiencies in capital utilization and underperformance compared to industry peers and the Sensex.

As of 20 November 2025, Sunil Healthcare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered overvalued based on its high PE ratio of 42.04, which significantly exceeds the industry average. Additionally, its EV to EBITDA stands at 10.06, while its ROCE is only 5.00%, suggesting inefficiencies in capital utilization compared to peers.<BR><BR>In comparison to its industry peers, Sunil Healthcare's valuation metrics are notably higher; for instance, Sun Pharma has a PE ratio of 36.94 and an EV to EBITDA of 24.4, while Cipla, another attractive peer, has a PE of 22.72 and an EV to EBITDA of 16.07. The PEG ratio for Sunil Healthcare is also low at 0.18, indicating potential growth relative to its price, but this does not sufficiently offset the concerns raised by its high valuation ratios. Furthermore, the company's stock has underperformed relative to the Sensex over various time frames, including a year-to-date return of -9.08% compared to the Sensex's 9.59%.

Why is Sunil Healthcare Ltd falling/rising?

As of 02-Feb, Sunil Healthcare Ltd's stock price is rising to 68.44, reflecting a 6.74% increase due to a trend reversal and positive financial results, including a 9.89% growth in net profit. Despite past underperformance and concerns about long-term fundamentals, the current rise is driven by strong short-term results and improved investor confidence.

As of 02-Feb, Sunil Healthcare Ltd's stock price is rising, currently at 68.44, reflecting a change of 4.32 or 6.74% increase. This upward movement can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after two consecutive days of decline. It opened with a significant gap up of 9.17% today and reached an intraday high of Rs 70. Additionally, the stock outperformed its sector by 6.81%, indicating strong relative performance.<BR><BR>The company has recently reported positive financial results, including a 9.89% growth in net profit and the highest operating cash flow of Rs 11.52 Cr. Furthermore, it has declared positive results for the last three consecutive quarters, which has likely bolstered investor confidence. Despite the stock's underperformance over the past year, with a return of -13.37%, its profits have increased significantly by 234.1%, suggesting a disconnect between stock performance and underlying profitability.<BR><BR>However, it is important to note that while the stock is currently rising, it has faced challenges such as weak long-term fundamental strength and a high debt to EBITDA ratio, which could impact future performance. Nonetheless, the current rise in stock price is primarily driven by positive short-term financial results and a reversal in recent price trends.

Which are the latest news on Sunil Healthcare?